Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
PPAR Res. 2008;2008:527048. doi: 10.1155/2008/527048.
During pregnancy crucial anatomic, physiologic, and metabolic changes challenge the mother and the fetus. The placenta is a remarkable organ that allows the mother and the fetus to adapt to the new metabolic, immunologic, and angiogenic environment imposed by gestation. One of the physiologic systems that appears to have evolved to sustain this metabolic regulation is mediated by peroxisome proliferator-activated receptors (PPARs). In clinical pregnancy-specific disorders, including preeclampsia, gestational diabetes, and intrauterine growth restriction, aberrant regulation of components of the PPAR system parallels dysregulation of metabolism, inflammation and angiogenesis. This review summarizes current knowledge on the role of PPARs in regulating human trophoblast invasion, early placental development, and also in the physiology of clinical pregnancy and its complications. As increasingly indicated in the literature, pregnancy disorders, such as preeclampsia and gestational diabetes, represent potential targets for treatment with PPAR ligands. With the advent of more specific PPAR agonists that exhibit efficacy in ameliorating metabolic, inflammatory, and angiogenic disturbances, further studies of their application in pregnancy-related diseases are warranted.
在妊娠期间,关键的解剖、生理和代谢变化对母亲和胎儿构成挑战。胎盘是一个非凡的器官,使母亲和胎儿能够适应妊娠带来的新的代谢、免疫和血管生成环境。似乎为了维持这种代谢调节而进化的生理系统之一是由过氧化物酶体增殖物激活受体(PPARs)介导的。在包括子痫前期、妊娠期糖尿病和胎儿宫内生长受限在内的妊娠特异性疾病中,PPAR 系统成分的异常调节与代谢、炎症和血管生成的失调平行。这篇综述总结了目前关于 PPAR 在调节人滋养细胞浸润、早期胎盘发育以及临床妊娠及其并发症的生理学中的作用的知识。正如文献中越来越多地指出的那样,子痫前期和妊娠期糖尿病等妊娠疾病代表了用 PPAR 配体治疗的潜在靶点。随着更特异的 PPAR 激动剂的出现,它们在改善代谢、炎症和血管生成紊乱方面显示出疗效,因此有必要进一步研究它们在与妊娠相关的疾病中的应用。